Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MOR

“We have an identity crisis. People say, ‘I knew every one of those songs, but I had no idea they were yours’”: Mike + The Mechanics’ history is a bit more rock’n’roll than Genesis’

Spurred on by surprise early success, Mike Rutherford’s band endured a tough time with a demon-haunted singer, then a replacement who expected rehearsals to be all thought and no action

3 Value Pharma Stocks to Keep Watching

3 Value Pharma Stocks to Keep Watching

The pharma industry’s ability to remain resilient in times of economic uncertainty offers an appealing investment opportunity. Hence, fundamentally sound pharma stocks Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), and Voyager Therapeutics (VYGR), which seem relatively undervalued to their peers, might be ideal additions to one’s watchlist. Read on.

First look inside Edinburgh city centre's breathtaking new Mor Bakehouse

First look inside Edinburgh city centre's breathtaking new Mor Bakehouse

The bakery chain originally opened up a shop on Princes Street called Mor Bakery late last year and now has a new location at Hunter Square, just off of the Royal Mile.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Best black jeans for women, from Good American, Levi’s, Tommy Hilfiger and more

Black jeans to love now and forever

Evening Standard

MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio

MorphoSys AG (NASDAQ:MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio is a biotechnology company based in South San Francisco that focuses on discovering and…

What people say about Mumbles restaurant with 'black book' of people who cancel without good reason

The decision has been backed by many, who feel it is a completely reasonable decision to 'stop the business losing money'

What's on in Dublin this weekend? Bowie Festival and other great events

The Easter bank holiday weekend sees a diverse array of events take place across Dublin

inkl

Read news from The Economist, FT, and more,
with one subscription

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

MorphoSys Discontinues US Discovery Activities, Takes €231M Impairment Charge

MorphoSys Discontinues US Discovery Activities, Takes €231M Impairment Charge

MorphoSys AG (NASDAQ:MOR) has reported a non-cash impairment charge of €231 million on goodwill after consolidating research and discovery functions. This write-down results from the consolidation of the Company's research and discovery activities after the acquisition of Constellation Pharmaceuticals. MorphoSys decided to focus its research activities on the most advanced programs and centralize…

Stocks That Hit 52-Week Lows On Tuesday

Stocks That Hit 52-Week Lows On Tuesday

Tuesday morning saw 454 companies set new 52-week lows.

1

People

Kritika SarmahHer

Mike Rutherford

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Board of Directors

Catalyst Pharmaceuticals Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

388,719 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play